



NEWS RELEASE

FOR IMMEDIATE RELEASE

CONTACT:

Sheryl Seapy
Pure Communications
949-608-0841

XDx and Bristol-Myers Squibb Enter into Pharmacogenomics Collaboration

Agreement Focused on Identifying Lupus Biomarkers for Orencia

BRISBANE, California, January 9, 2009 – XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, announced today that it has signed a collaborative pharmacogenomics agreement with Bristol-Myers Squibb Company (NYSE: BMY). The collaboration is focused on identifying biomarkers in the field of Systemic Lupus Erythematosus (SLE) for clinical diagnostic purposes associated with the clinical development of Orencia® (abatacept), a Bristol-Myers Squibb drug approved for the treatment of rheumatoid arthritis.

Bristol-Myers Squibb will make an upfront payment to XDx in addition to milestone payments upon the successful achievement of specific research and development objectives. XDx will receive commercial rights to certain diagnostic applications resulting from the collaboration.

“This collaborative agreement with Bristol-Myers Squibb further underscores our leadership in gene expression technologies and analysis applied to molecular diagnostics and demonstrates our ongoing commitment to patients battling serious immune-mediated disorders such as lupus,” said Pierre Cassigneul, president and chief executive officer, XDx. “We are pleased to be working with our new partners at Bristol-Myers Squibb and we intend to continue leveraging our R&D, clinical, and bioinformatics capabilities through partnerships to further demonstrate the utility of our innovative biomarker identification technologies and diagnostic work in autoimmune disease.”

About XDx

Based in Brisbane, California, XDx is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed a proprietary new method for noninvasively monitoring immune system activity by measuring gene expression in a patient's peripheral blood. This work is the basis for AlloMap® Molecular Expression Testing, which provides transplant physicians with a new tool to aid in the identification of the probability of acute cellular rejection for post-cardiac transplant patient management.

In August 2008, XDx announced that it received market clearance from the U.S. Food and Drug Administration (FDA) for AlloMap Molecular Expression Testing. The AlloMap Test is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) test service, performed in a single laboratory, assessing the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing, in conjunction with standard clinical assessment. XDx is the first molecular diagnostics company to obtain FDA clearance of an IVDMIA for use in immunology.

XDx is evaluating its gene expression discovery and development platform for use in other immune-mediated conditions. XDx is conducting the Systemic Lupus Erythematosus Activity Gene Expression (SAGE) Study, which follows individuals with a known diagnosis of SLE for changes in disease activity during the course of one year. The goal is to develop new blood tests to help clinicians accurately predict which lupus patients will flare, when the flares will occur, and the flare severity.

SLE is a systemic, chronic autoimmune disorder that affects more than 300,000 people in the United States. Clinical management of patients with SLE is complicated by the recurrence of disease flares, which can vary in timing and severity and result in hospitalization, and by disease progression including kidney failure and damage to other organs.

Some of the AlloMap Molecular Expression Technology developed and implemented by XDx in heart transplant patient management may be applicable to other diseases that involve transplant rejection and the immune system. XDx's noninvasive technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.

###